From precision interventions to precision health
N
Nicholas J. Schork
L
Laura H. Goetz
Abstract
Abstract Precision medicines, or those medicines that are tailored to individual genetic, molecular, physiologic, behavioral, and/or exposure profiles, are being developed at a rapid pace. However, just how precise these interventions are in terms of their mechanisms of action (MOAs), clinical effects, and utility in different individuals, are hard anticipate with current preclinical research and clinical trials strategies. To understand how various genes, processes, organs, clinical phenotypes, etc. may be impacted by an intervention, as well as how many people might benefit from it, appropriate data on living human beings needs to be collected as part of built-for-purpose clinical trials.
Article Details
Journal
Nature Communications
Volume / Issue
Vol. 16, Issue 1
Published
May 30, 2025
ISSN
2041-1723
Publisher
Nature Portfolio
Authors (2)
N
Nicholas J. Schork
L
Laura H. Goetz
Related Articles from this Journal
Synthesis of adaptive 15N-nitrosyl-Co7 nanocluster for electrocatalytic C–H functionalization
Chao Wu, Xu Zhang et al.
Aug 2026
10.1038/s41467-026-76516-1
Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses
Connor Weidle, Natalie Brunette et al.
Aug 2026
10.1038/s41467-026-76114-1
Multi-population GWAS meta-analysis identifies bladder cancer susceptibility loci and highlights genetic regulation of smoking-related risk
Ludmila Prokunina-Olsson, Oscar Florez-Vargas et al.
Aug 2026
10.1038/s41467-026-76157-4
Genome-wide annotation of human multi-nucleotide variants reveals widespread functional differences from single nucleotide variants
Weiwei Jin, Wen Cao et al.
Aug 2026
10.1038/s41467-026-76470-y
Allele-specific chromatin architecture shapes imprinted domains and coordinates a distal enhancer and antisense transcription at the mouse Mest-Copg2 domain
Bongmin Bae, Katherine Gu et al.
Aug 2026
10.1038/s41467-026-76506-3